HCRN GU22-598: what clinicians are saying
enfortumab vedotin plus pembrolizumab in muscle-invasive urothelial cancer of the bladder · NCT06809140 ↗ · Phase 2 · Matthew Galsky
The clinicians cited distinguish HCRN GU22-598 by its stringent biopsy assessment, qualifying broader concern that apparent clearance may conceal cancer. Much of the debate concerns EV209: one physician supports maintaining planned EV–pembrolizumab exposure to isolate the effect of omitting surgery, while another favors earlier stopping for exceptional responders because of neuropathy risk. No target-trial outcomes are reported in the sources reviewed for this edition.
Created with AI · how we check it
- edition 1
- commentary checked Nov 17, 2026
- 173 verified statements
This edition $1,250, with MCP access for your AI agent. Get this report
13 findings, and what sits behind each
01. Clinical complete response: why some clinicians question its use alone to omit cystectomy
4 of the report's 14 cited clinicians · 14 statements from 5 speakers in 6 sources, 1 of them a podcast or video · 17 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Complete response rate with enfortumab vedotin plus pembrolizumab for MIBC, The comparison, Design and conduct, Primary endpoint: Bladder-intact event-free survival (BIEFS) in patients achieving a clinical complete response, Population and setting.
02. Complete response: why some speakers ask if it proves durable local control and cure
5 of the report's 14 cited clinicians · 16 statements from 7 speakers in 5 sources, 1 of them a podcast or video · 14 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Bladder-intact event-free survival (BIEFS) in patients achieving a clinical complete response, Secondary endpoints, Design and conduct, The comparison.
03. Bladder sparing: where speakers split on fixed versus response-adapted duration
7 of the report's 14 cited clinicians · 20 statements from 9 speakers in 2 sources, 1 of them a podcast or video · 17 passages
Limitations recorded: 3.
Draws on: The comparison, Design and conduct, Safety and tolerability.
04. Bladder sparing: what most clinicians highlight about toxicity with prolonged treatment
7 of the report's 14 cited clinicians · 27 statements from 7 speakers in 4 sources, 1 of them a podcast or video · 23 passages
Limitations recorded: 4.
Draws on: Safety and tolerability, Secondary endpoints.
05. CtDNA/utDNA: most speakers question readiness, but some propose guided care
6 of the report's 14 cited clinicians · 16 statements from 7 speakers in 3 sources, 1 of them a podcast or video · 16 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Complete response rate with enfortumab vedotin plus pembrolizumab for MIBC, Primary endpoint: Bladder-intact event-free survival (BIEFS) in patients achieving a clinical complete response, Safety and tolerability.
06. Surgery omission: most speakers value trials, but most note a trial's limits
3 of the report's 14 cited clinicians · 21 statements from 5 speakers in 3 sources, 1 of them a podcast or video · 24 passages
Limitations recorded: 4.
Draws on: Design and conduct, The comparison, Primary endpoint: Complete response rate with enfortumab vedotin plus pembrolizumab for MIBC, Primary endpoint: Bladder-intact event-free survival (BIEFS) in patients achieving a clinical complete response, Secondary endpoints, Population and setting.
07. Bladder preservation: what speakers say
6 of the report's 14 cited clinicians · 25 statements from 9 speakers in 4 sources, 1 of them a podcast or video · 26 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Bladder-intact event-free survival (BIEFS) in patients achieving a clinical complete response, Design and conduct, Secondary endpoints, Primary endpoint: Complete response rate with enfortumab vedotin plus pembrolizumab for MIBC, The comparison, Safety and tolerability.
08. VOLGA: where speakers split on using future duration data across regimens
3 of the report's 14 cited clinicians · 24 statements from 4 speakers in 3 sources, 1 of them a podcast or video · 32 passages
Limitations recorded: 5.
Draws on: Design and conduct, Secondary endpoints, Population and setting, Safety and tolerability.
09. Perioperative MIBC: why speakers favor more individualized treatment
2 of the report's 14 cited clinicians · 9 statements from 3 speakers in 4 sources, 1 of them a podcast or video · 5 passages
Limitations recorded: 3.
Draws on: Population and setting, Design and conduct.
Beyond the trial population
10. Radiation and salvage: where clinicians split on local treatment after clinical CR
3 of the report's 14 cited clinicians · 11 statements from 3 speakers in 2 sources, 1 of them a podcast or video · 13 passages
Limitations recorded: 4.
11. After clinical CR: which options most speakers would test for bladder sparing
2 of the report's 14 cited clinicians · 6 statements from 3 speakers in 2 sources, 1 of them a podcast or video · 7 passages
Limitations recorded: 3.
12. T4 response: some clinicians question clinical CR; a speaker proposes stage limits
3 of the report's 14 cited clinicians · 11 statements from 4 speakers in 2 sources, 1 of them a podcast or video · 13 passages
Limitations recorded: 3.
13. Bladder sparing: how speakers use earlier and metastatic studies as context
3 of the report's 14 cited clinicians · 11 statements from 4 speakers in 5 sources, 1 of them a podcast or video · 6 passages
Limitations recorded: 4.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 13
4 of the report's 14 cited clinicians
Clinical complete response: why some clinicians question its use alone to omit cystectomy
14 statements from 5 speakers in 6 sources, 1 of them a podcast or video
2 of the 5 named speakers in this finding hold this view, each a confirmed clinician
- 14
- statements
- 17
- passages
- 6
- sources
- 5
- speakers
What the statements areViews 6Questions and uncertainty 2Clinical experience 0Comparisons 2Restated results and context 4Statement-to-passage links (a passage can back several statements)Supporting a statement 18Giving context 0Recorded with the findingLimitations: 3
4 posts and articles · 1 podcast or video · 1 registry
Draws on: Primary endpoint: Complete response rate with enfortumab vedotin plus pembrolizumab for MIBC, The comparison, Design and conduct, Primary endpoint: Bladder-intact event-free survival (BIEFS) in patients achieving a clinical complete response, Population and setting.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
4 of the 13 findings and 28 of the 173 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (4)
CR, complete response; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians.
The full HCRN GU22-598 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What evidence linking clinical to pathological complete response do clinicians need before clinical complete response can guide cystectomy omission after enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer?
From finding F1 (14 statements from 5 speakers in 6 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 20commentary sources screened
- 12sources cited by verified statements
- 22named in screened sources
- 22speakers cited in the report
- 20cited speakers with a verified identity
14 cited clinicians, speakers with a confirmed clinical role, of them 14 physicians. By role and specialty:
- 8 physician, specialty not confirmed
- 3 physician, Medical oncology
- 1 physician, Radiation oncology
- 1 physician, Surgical oncology
- 1 physician, Urology
Also in the sources: 1 organizational or shared account, not counted as people.
- 173verified statements, each linked to its source
- 87of them from speakers with a confirmed clinical role
- 13findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 13 | Titles free |
| Detailed analysis | 15 sections | Paid |
| Verified statements with short source quotes and links | 173 | Paid |
| Who said each statement: the cited speakers | 22 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 14 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 20 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 11 | Free |
| Sources with links | 12 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
11 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Complete response rate with enfortumab vedotin plus pembrolizumab for MIBC | 10 | 5 |
| Primary endpoint: Bladder-intact event-free survival (BIEFS) in patients achieving a clinical complete response | 10 | 3 |
| Secondary endpoints | 9 | 4 |
| Population and setting | 14 | 4 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 15 | 2 |
| Safety and tolerability | 24 | 3 |
| Design and conduct | 27 | 2 |
| ctDNA, utDNA and multimodal selection for bladder preservation | 19 | 4 |
| Systemic-treatment duration and the contribution of postoperative therapy | 44 | 3 |
| Patient priorities, quality of life and the burden of retaining the bladder | 13 | 3 |
| Routine-care adoption, informed consent and prospective evidence | 16 | 5 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
173 verified statements from 12 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 111 statements · 64% | ||||
| Podcasts | 111 | 1 | 1 | |
| Posts · 60 statements · 35% | ||||
| X threads | 60 | 10 | 19 | |
| Primary sources · 2 statements · 1%cited for context, not screened | ||||
| Registry | 2 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 8 / quarter
- Screened window
- Jun 27, 2025 → Nov 14, 2026
- Cited window
- Jun 27, 2025 → Nov 14, 2026
- Retrieved
- Nov 17, 2026
The trial
from ClinicalTrials.gov- Title
- Phase 2 Trial of Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Urothelial Cancer of the Bladder
- Registry
- NCT06809140
- Study IDs
- HCRN-GU22-598
- Sponsor
- Matthew Galsky
- Collaborators
- Seagen Inc., Astellas Pharma Inc, Merck Sharp & Dohme LLC, Icahn School of Medicine at Mount Sinai
- Design
- Phase 2 · Interventional, single group
- Status
- Recruiting
- Enrollment
- 75 estimated
- Registered
- 2025-02-05
- Start
- 2025-04-07 actual
- Primary completion
- 2027-11 estimated
- Primary endpoints
- Complete response rate with enfortumab vedotin plus pembrolizumab for MIBC
- Bladder-intact event-free survival (BIEFS) in patients achieving a clinical complete response
- Interventions
- 2 registered
More on: Urothelial carcinoma, enfortumab vedotin, pembrolizumab
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a question about current treatment perspectives on selective bladder sparing in muscle-invasive bladder cancer; a view on response assessment and treatment duration when considering bladder sparing after systemic therapy for muscle-invasive bladder cancer; a question about the lack of comparative evidence for selective bladder sparing with systemic treatment; a remark on the provenance of relayed commentary about bladder-sparing treatment for muscle-invasive bladder cancer; a view on the practical ease of administering EV–pembrolizumab versus platinum chemotherapy; a view on the relative administration burden of enfortumab vedotin plus pembrolizumab versus platinum chemotherapy.
- 22 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 39 sources about other trials or topics are not included.
- The sources reviewed for this edition contain registry methods and commentary, not an outcome report for NCT06809140. No target-trial efficacy, safety or equivalence conclusion can be drawn from these views.
Show all 11 known gaps +Fewer −
- The most detailed debate concerns the separate EV209 study. Its 240-patient descriptions, treatment-assessment schedule and methodological defenses must not be treated as the target protocol.
- Some episode passages cannot be attributed to a named speaker. Guest lists and recurring transcript labels do not resolve who said those passages.
- The sources are not a representative sample of HCPs. Source totals, reposts, parallel-language accounts and repeated appearances by the same people do not establish prevalence, independence or consensus.
- Several figures were recalled approximately, questioned or used hypothetically. In particular, treatment-completion and mortality exchanges do not establish reliable exposure-specific death rates.
- Earlier-study results, metastatic observations, alternative regimens and proposed biomarker-defined strategies remain attributed context; they do not become results or validated selection rules for this trial.
- The discussion uses EV209 or EV-209, and one reply uses EV208. These descriptions concern a separate surgery-omission study and must not be merged with the target HCRN GU22-598 protocol.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 17, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. HCRN GU22-598 (NCT06809140): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 17, 2026. https://www.erudio.com/reports/hcrn-gu22-598-nct06809140
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "HCRN GU22-598" (NCT06809140), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "hcrn-gu22-598-nct06809140". If you cannot make requests, read https://www.erudio.com/reports/hcrn-gu22-598-nct06809140.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT06809140", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT06809140 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/hcrn-gu22-598-nct06809140.json
curl https://www.erudio.com/reports/hcrn-gu22-598-nct06809140.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "hcrn-gu22-598-nct06809140" })release 8b04816ef3cb2e1ec8f83963ca119838b152e7a6c567485a2464b13a2f450f44
Questions
How much does the HCRN GU22-598 report cost?
One edition costs $1,250 (Standard · 173 verified statements · 87 from 14 confirmed clinicians). With updates: 3 months $2,200, 6 months $3,100, 12 months $4,400. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the HCRN GU22-598 report cover?
173 statements from 12 sources (1 podcast, 10 posts, 1 registry record), 87 of them from 14 confirmed clinicians, each linked to its source. Commentary checked Nov 17, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the HCRN GU22-598 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "hcrn-gu22-598-nct06809140" }) previews it and create_order({ "report": "hcrn-gu22-598-nct06809140", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the HCRN GU22-598 report?
Edition 1 (version 1.0.0), accepted Nov 17, 2026 UTC; last checked for new commentary Nov 17, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.